Trial Profile
A Randomised, Placebo-controlled Single-dose, Parallel-group, Double-blind Trial Evaluating Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Japanese Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Mar 2017
Price :
$35
*
At a glance
- Drugs Catridecacog (Primary)
- Indications Factor XIII deficiency
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 24 Mar 2017 New trial record